Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
12 results
  • Head and Neck Cancer, Cervical Cancer, Breast Cancer, Ovarian Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Bladder Cancer, Cervical Cancer, Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Endometrial Cancer

25-816          Phase I

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary anti-Tumor Activity of STRO-004 in Adults with Refractory/Recurrent Metastatic Solid Tumors

  • Esophageal Cancer, Head and Neck Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Breast Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer

25-490          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors

  • Lung Cancer, Pancreatic Cancer, Prostate Cancer, Ovarian Cancer, Melanoma, Head and Neck Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Kidney Cancer, Head and Neck Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Bladder Cancer, Gastric (Stomach) Cancer

25-448          Phase II

A Phase 1/2 Study of GEN1286 in Patients with Advanced Solid Tumors

  • Lung Cancer, Kidney Cancer, Head and Neck Cancer, Cervical Cancer, Bladder Cancer, Breast Cancer

25-855          Phase II

A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, a Nectin4/Trop2 ADC, as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors

  • Head and Neck Cancer, Metastatic/Advanced Cancer, Breast Cancer, Cervical Cancer, Gastric (Stomach) Cancer

25-075          Phase II

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

  • Bladder Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

24-353          Phase I

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

  • Ovarian Cancer, Metastatic/Advanced Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer, Endometrial Cancer

23-618          Phase I

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

Showing 1 - 10 of 12 results